Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ASC43F in Healthy Subjects
NCT05118516Phase 1Completed
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ASC43F in Nonalcoholic steatohepatitis (NASH), sponsored by Gannex Pharma Co., Ltd. Primary endpoint: Incidence of treatment emergent adverse events at Day 7. Started Nov 2021; status: completed.
02
Drugs
ASC43F
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05118516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05118516.